Alexander Gintsburg, director of the Gamaleya Center, states preclinical animal trials show >90% efficacy.
The Blokhin Cancer Research Centre has received approval for clinical use.
Unlike preventive mRNA COVID vaccines, this is a therapeutic cancer vaccine. It's designed to train a patient's immune system to recognize and destroy specific mutations (neoantigens) present on their melanoma cells, offering a personalized treatment approach.